Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

22 Nov 2022

Abstract excerpt

Treatment with CD19-directed CAR T-cells has evolved as a standard of care for relapsed or refractory large B-cell lymphoma (r/r LBCL). As LBCL is largely a disease of the elderly, age limitations of CAR T-cell therapy may affect its applicability. Notably, age has not been among the unfavorable predictors of progression-free survival (PFS) in our recent analysis of commercial use of axicabtagene ciloleucel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36418916
DOI: 10.1038/s41409-022-01867-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experiencePMID 36418916Read ↗

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaSemantic proximity Read ↗

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The NetherlandsSemantic proximity Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.Semantic proximity Read ↗

Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal Region B cell lymphomaSemantic proximity Read ↗

Next-Generation Chimeric Antigen Receptor T-cellsSemantic proximity Read ↗

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST studySemantic proximity Read ↗

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal B cell lymphomaSemantic proximity Read ↗

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.Semantic proximity Read ↗

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Semantic proximity Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.